NO20054018L - Intranasal formulering av rotigotin - Google Patents

Intranasal formulering av rotigotin

Info

Publication number
NO20054018L
NO20054018L NO20054018A NO20054018A NO20054018L NO 20054018 L NO20054018 L NO 20054018L NO 20054018 A NO20054018 A NO 20054018A NO 20054018 A NO20054018 A NO 20054018A NO 20054018 L NO20054018 L NO 20054018L
Authority
NO
Norway
Prior art keywords
rotigotine
intranasal formulation
intranasal
moisturizing
cyclodextrin
Prior art date
Application number
NO20054018A
Other languages
English (en)
Norwegian (no)
Inventor
Robert Kraemer
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of NO20054018L publication Critical patent/NO20054018L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20054018A 2003-12-23 2005-08-30 Intranasal formulering av rotigotin NO20054018L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03029680A EP1547592A1 (en) 2003-12-23 2003-12-23 Intranasal formulation of rotigotine
PCT/EP2004/014626 WO2005063236A1 (en) 2003-12-23 2004-12-22 Intranasal formulation of rotigotine

Publications (1)

Publication Number Publication Date
NO20054018L true NO20054018L (no) 2005-08-30

Family

ID=34530709

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054018A NO20054018L (no) 2003-12-23 2005-08-30 Intranasal formulering av rotigotin

Country Status (27)

Country Link
US (1) US7683040B2 (sr)
EP (2) EP1547592A1 (sr)
JP (1) JP4430067B2 (sr)
KR (1) KR100718760B1 (sr)
CN (1) CN100374112C (sr)
AT (1) ATE326961T1 (sr)
AU (1) AU2004308641B2 (sr)
BR (1) BRPI0407845A (sr)
CA (1) CA2516400C (sr)
CY (1) CY1105131T1 (sr)
DE (1) DE602004000982T2 (sr)
DK (1) DK1605932T3 (sr)
EA (1) EA008005B1 (sr)
ES (1) ES2262122T3 (sr)
HR (1) HRP20060240T3 (sr)
IL (1) IL170297A (sr)
IS (1) IS2310B (sr)
MX (1) MXPA05008909A (sr)
NO (1) NO20054018L (sr)
NZ (1) NZ541875A (sr)
PL (1) PL1605932T3 (sr)
PT (1) PT1605932E (sr)
RS (1) RS50534B (sr)
SI (1) SI1605932T1 (sr)
UA (1) UA79196C2 (sr)
WO (1) WO2005063236A1 (sr)
ZA (1) ZA200506550B (sr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
DK1426049T3 (da) 2002-12-02 2005-08-22 Sanol Arznei Schwarz Gmbh Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
PL2215072T3 (pl) 2007-11-28 2015-12-31 Ucb Pharma Gmbh Polimorficzna postać rotygotyny
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
WO2011076879A1 (en) 2009-12-22 2011-06-30 Ucb Pharma Gmbh Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
WO2013075822A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system (tts) with rotigotine
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
CN103768043B (zh) * 2012-10-22 2015-12-09 苏州药明康德新药开发股份有限公司 采用羟丙基-β-环糊精配制四氢化萘类化合物均一稳定溶液的方法
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片
CN105358139B (zh) 2013-07-03 2020-10-16 Lts罗曼治疗方法有限公司 具有电子元件的经皮治疗系统
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
JP6573913B2 (ja) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
ES2954087T3 (es) 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
CN110917125B (zh) * 2020-01-02 2022-08-12 安徽中医药大学 一种罗替戈汀鼻用胶束温敏凝胶的制备方法
CN115485027A (zh) 2020-03-24 2022-12-16 思瑞诺医疗有限公司 冠状病毒感染引起的化学感觉功能障碍的治疗
EP4460291A1 (en) * 2022-01-06 2024-11-13 Cyrano Therapeutics, Inc. Improved nasal administration of parkinson's therapeutics
CN120053353A (zh) * 2024-05-31 2025-05-30 纳索菲德(上海)制药技术有限公司 一种巴氯芬鼻脑递释组合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108991A (en) 1975-06-19 1992-04-28 Whitby Research, Inc. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US5218113A (en) 1986-01-31 1993-06-08 Whitby Research, Inc. N-substituted thiolactams
US4992422A (en) 1986-01-31 1991-02-12 Whitby Research, Inc. Compositions comprising 1-substituted azacycloalkanes
CA1293192C (en) 1986-01-31 1991-12-17 James V. Peck Compositions comprising 1-substituted azacycloalkanes
US4755535A (en) 1986-04-23 1988-07-05 Nelson Research & Development Co. Compositions comprising 1-substituted azacycloalkenes
US5073544A (en) 1986-08-15 1991-12-17 Whitby, Inc. Transdermal compositions of 1-oxohydrocarbyl-substituted azacyclohexanes
US4902676A (en) 1986-09-29 1990-02-20 Nelson Research & Development Co. Compositions comprising N,N-dialkylalkanamides
ES2032570T3 (es) 1987-11-20 1993-02-16 Farmitalia Carlo Erba S.R.L. Derivados antiparkinson de ergolina. (reserva del art. 167.2 cpe).
US5472946A (en) 1988-04-08 1995-12-05 Peck; James V. Transdermal penetration enhancers
US5073844A (en) * 1991-01-11 1991-12-17 The Annlouise Partnership Lighted baggage piece
US6086905A (en) 1991-03-21 2000-07-11 Peck; James V. Topical compositions useful as skin penetration barriers
US5308625A (en) 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US5989586A (en) 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
GB9324018D0 (en) 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
PT766578E (pt) 1994-06-24 2001-01-31 Cygnus Therapeutic Systems Dispositivo de colheita iontoforetica de amostras
US5771890A (en) 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
AUPQ969800A0 (en) 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
ES2204780T3 (es) 2001-05-08 2004-05-01 Schwarz Pharma Ag Sistema terapeutico transdermico para la enfermedad de parkinson que induce altos niveles de rotigotina en plasma.
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
HU227543B1 (en) 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
BR0309259A (pt) 2002-04-18 2005-02-09 Pharmacia Corp Terapia combinada para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox 2)
JP4288263B2 (ja) 2002-10-25 2009-07-01 コレジウム ファーマシューティカル, インク. p−ヒドロキシ−ミルナシプランの立体異性体およびその使用方法
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
US20050032873A1 (en) 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
JP2007518754A (ja) 2004-01-22 2007-07-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング モノアミン神経伝達物質再取込みインヒビターとドーパミンアゴニストを含む医薬組成物
DE502005003491D1 (de) 2004-08-02 2008-05-08 Sanol Arznei Schwarz Gmbh Carboxamide des indolizins und seiner aza- und diazaderivate
DE102004054634A1 (de) 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide

Also Published As

Publication number Publication date
UA79196C2 (en) 2007-05-25
CN1777422A (zh) 2006-05-24
CA2516400C (en) 2009-10-27
HK1083596A1 (en) 2006-07-07
CY1105131T1 (el) 2009-11-04
EA008005B1 (ru) 2007-02-27
DK1605932T3 (da) 2006-09-18
EP1605932A1 (en) 2005-12-21
HRP20060240T3 (hr) 2007-05-31
ZA200506550B (en) 2006-05-31
PT1605932E (pt) 2006-08-31
JP2006526004A (ja) 2006-11-16
BRPI0407845A (pt) 2006-02-14
ATE326961T1 (de) 2006-06-15
IL170297A (en) 2010-06-30
EA200501159A1 (ru) 2006-02-24
AU2004308641A1 (en) 2005-07-14
WO2005063236A1 (en) 2005-07-14
JP4430067B2 (ja) 2010-03-10
US20070191308A1 (en) 2007-08-16
IS8487A (is) 2006-05-26
KR100718760B1 (ko) 2007-05-15
CA2516400A1 (en) 2005-07-14
SI1605932T1 (sl) 2006-08-31
CN100374112C (zh) 2008-03-12
NZ541875A (en) 2008-08-29
US7683040B2 (en) 2010-03-23
AU2004308641B2 (en) 2006-10-26
EP1547592A1 (en) 2005-06-29
EP1605932B1 (en) 2006-05-24
MXPA05008909A (es) 2005-10-05
ES2262122T3 (es) 2006-11-16
RS50534B (sr) 2010-05-07
DE602004000982D1 (de) 2006-06-29
IS2310B (is) 2007-11-15
PL1605932T3 (pl) 2006-09-29
DE602004000982T2 (de) 2007-05-10
KR20060040578A (ko) 2006-05-10

Similar Documents

Publication Publication Date Title
PT1605932E (pt) Formulacao intranasal da rotigotina
NO20080164L (no) N-(pyridin-2-yl)-sulfonamidderivater
NO20012921L (no) Fenylglycin-derivater
TR200302105T4 (tr) Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
NO20040356L (no) Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
EP1539122A4 (en) PHARMACEUTICAL AQUEOUS 2,6-DIISOPROPYLPHENOL COMPOSITIONS
NO20065878L (no) Terapeutiske forbindelser
BR0209020A (pt) Composição farmacêutica de polialilamina
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
SE0101932D0 (sv) Pharmaceutical combinations
NO20062051L (no) Farmasoytisk virkestoffinneholdende formulering med belegg
PT1556371E (pt) Derivados de benzimidazole e sua utilizacao como pro-farmacos de inibadores da bomba de protoes.
NO20063178L (no) Progabalinpreparat
NO20064521L (no) Framgangsmate og blanding for behandling av rhinitt
NO20001781L (no) 3-amino-3-arylpropan-1-og lignende-derivater, deres fremstilling og anvendelse
ATE357212T1 (de) Wässrige pharmazeutische lösung enthaltend oxymetazolin und/oder xylometazolin
AR031649A1 (es) Composicion farmaceutica de dronedarona para administracion parenteral
NO20061702L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist
HUP0202324A2 (hu) Prukaloprid orális oldat
NO20055367L (no) Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst
EP1362590A8 (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
DK1411956T3 (da) Anvendelse af oversulfaterede polysaccharider som inhibitorer af HIV
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
ATE528003T1 (de) Wässrige, flüssigkeitszubereitungen und lichtstabilisierte wässrige flüssigkeitszubereitungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application